

Chapter 187

Lyme Borreliosis

Meera Mahalingam, Jag Bhawan,
Daniel B. Eisen, & Linden Hu

REFERENCES

1. Centers for Disease Control and Prevention (CDC): Lyme disease—United States, 2001–2002. *MMWR Morb Mortal Wkly Rep* **53**:365, 2004
2. Steere AC et al: Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum. *Ann Intern Med* **86**:685, 1977
3. Burgdorfer W et al: Lyme disease—a tick-borne spirochetosis? *Science* **216**:1317, 1982
4. Benach JL et al: Spirochetes isolated from the blood of two patients with Lyme disease. *N Engl J Med* **308**:740, 1983
5. Steere AC et al: The early clinical manifestations of Lyme disease. *Ann Intern Med* **99**:76, 1983
6. Ackermann R et al: Ixodes ricinus spirochete and European erythema chronicum migrans disease. *Yale J Biol Med* **57**:573, 1984
7. Aguero-Rosenfeld ME et al: Diagnosis of Lyme borreliosis. *Clin Microbiol Rev* **18**:484, 2005
8. Asbrink E: Erythema chronicum migrans Afzelius and acrodermatitis chronica atrophicans. Early and late manifestations of Ixodes ricinus-borne Borrelia spirochetes. *Acta Derm Venereol Suppl (Stockh)* **118**:1, 1985
9. Hoen AG et al: Phylogeography of Borrelia burgdorferi in the eastern United States reflects multiple independent Lyme disease emergence events. *Proc Natl Acad Sci U S A* **106**:15013, 2009
10. Bacon RM, Kugeler KJ, Mead PS: Surveillance for Lyme disease—United States, 1992–2006. *MMWR Surveill Summ* **57**:1, 2008
11. O’Connell S et al: Epidemiology of European Lyme borreliosis. *Zentralbl Bakteriol* **287**:229, 1998
12. Singh SK, Girschick HJ: Lyme borreliosis: From infection to autoimmunity. *Clin Microbiol Infect* **10**:598, 2004
13. Dennis DT, Hayes E: Epidemiology of Lyme borreliosis. In: *Lyme borreliosis: Biology, Epidemiology and Control*, edited by O Kahl et al Oxford, United Kingdom, CABI Publishing, 2002, p. 251
14. Saint Girons I et al: Identification of Borrelia burgdorferi sensu lato species in Europe. *Zentralbl Bakteriol* **287**:190, 1998
15. Fraser CM et al: Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. *Nature* **390**:580, 1997
16. Stanek G, Strle F: Lyme borreliosis. *Lancet* **362**:1639, 2003
17. Picken RN et al: Patient isolates of Borrelia burgdorferi sensu lato with genotypic and phenotypic similarities of strain 25015. *J Infect Dis* **174**:1112, 1996
18. Varela AS et al: First culture isolation of Borrelia lonestari, putative agent of southern tick-associated rash illness. *J Clin Microbiol* **42**:1163, 2004
19. van Dam AP et al: Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. *Clin Infect Dis* **17**:708, 1993
20. Mather TN et al: Comparing the relative potential of rodents as reservoirs of the Lyme disease spirochete (Borrelia burgdorferi). *Am J Epidemiol* **130**:143, 1989
21. Richter D et al: Competence of American robins as reservoir hosts for Lyme disease spirochetes. *Emerg Infect Dis* **6**:133, 2000
22. Telford SR III et al: Incompetence of deer as reservoirs of the Lyme disease spirochete. *Am J Trop Med Hyg* **39**:105, 1988
23. Burgdorfer W, Hayes SF, Corwin D: Pathophysiology of the Lyme disease spirochete, Borrelia burgdorferi, in ixodid ticks. *Rev Infect Dis* **11**(Suppl. 6):S1442, 1989
24. Krause PJ et al: Disease-specific diagnosis of coinfecting tickborne zoonoses: Babesiosis, human granulocytic ehrlichiosis, and Lyme disease. *Clin Infect Dis* **34**:1184, 2002
25. Hunfeld KP et al: Seroprevalence of Babesia infections in humans exposed to ticks in midwestern Germany. *J Clin Microbiol* **40**:2431, 2002
26. Steere AC: Lyme disease. *N Engl J Med* **345**:115, 2001
27. Schwan TG, Piesman J: Vector interactions and molecular adaptations of Lyme disease and relapsing fever spirochetes associated with transmission by ticks. *Emerg Infect Dis* **8**:115, 2002

28. Ojaimi C et al: Profiling of temperature-induced changes in *Borrelia burgdorferi* gene expression by using whole genome arrays. *Infect Immun* **71**:1689, 2003
29. Schwan TG, Piesman J: Temporal changes in outer surface proteins A and C of the Lyme disease-associated spirochete, *Borrelia burgdorferi*, during the chain of infection in ticks and mice. *J Clin Microbiol* **38**:382, 2000
30. Burkot TR, Piesman J, Wirtz RA: Quantitation of the *Borrelia burgdorferi* outer surface protein A in *Ixodes scapularis*: Fluctuations during the tick life cycle, doubling times, and loss while feeding. *J Infect Dis* **170**:883, 1994
31. Pal U et al: TROSPA, an *Ixodes scapularis* receptor for *Borrelia burgdorferi*. *Cell* **119**:457, 2004
32. Piesman J: Dynamics of *Borrelia burgdorferi* transmission by nymphal *Ixodes dammini* ticks. *J Infect Dis* **167**:1082, 1993
33. Ramamoorthi N et al: The Lyme disease agent exploits a tick protein to infect the mammalian host. *Nature* **436**:573, 2005
34. Deruaz M et al: Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. *J Exp Med* **205**:2019, 2008
35. Kraiczy P: Immunological characterization of the complement regulator factor H-binding CRASP and Erp proteins of *Borrelia burgdorferi*. *Int J Med Microbiol* **37**:152, 2004
36. McDowell JV et al: Comprehensive analysis of the factor h binding capabilities of borrelia species associated with Lyme disease: Delineation of two distinct classes of factor h binding proteins. *Infect Immun* **71**:3597, 2003
37. Zhao Z et al: Selective up-regulation of matrix metalloproteinase-9 expression in human erythema migrans skin lesions of acute Lyme disease. *J Infect Dis* **188**:1098, 2003
38. Wang X et al: Relative contributions of innate and acquired host responses to bacterial control and arthritis development in Lyme disease. *Infect Immun* **73**:657, 2005
39. Fikrig E et al: Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. *Science* **250**:553, 1990
40. Kochi SK, Johnson RC, Dalmasso AP: Complement-mediated killing of the Lyme disease spirochete *Borrelia burgdorferi*. Role of antibody in formation of an effective membrane attack complex. *J Immunol* **146**:3964, 1991
41. Bockenstedt LK et al: *Borrelia burgdorferi* infection and immunity in mice deficient in the fifth component of complement. *Infect Immun* **61**:2104, 1993
42. Liu N et al: Myeloid differentiation antigen 88 deficiency impairs pathogen clearance but does not alter inflammation in *Borrelia burgdorferi*-infected mice. *Infect Immun* **72**:3195, 2004
43. Radolf J: Posttreatment chronic Lyme disease—what it is not. *J Infect Dis* **192**:948, 2005
44. Wooten RM et al: Toll-like receptor 2 is required for innate, but not acquired, host defense to *Borrelia burgdorferi*. *J Immunol* **168**:348, 2002
45. Cinco M et al: Interaction with *Borrelia burgdorferi* causes increased expression of the CR3 integrin and increased binding affinity to fibronectin via CR3. *J Mol Microbiol Biotechnol* **2**:575, 2000
46. Behera AK et al: Identification of a TLR-independent pathway for *Borrelia burgdorferi*-induced expression of matrix metalloproteinases and inflammatory mediators through binding to integrin alpha 3 beta 1. *J Immunol* **177**:657, 2006
47. Akin E et al: The immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged Lyme arthritis and the IgG response to P35 correlates with mild and brief arthritis. *Infect Immun* **67**:173, 1999
48. Krause A et al: T cell proliferation induced by *Borrelia burgdorferi* in patients with Lyme borreliosis. Autologous serum required for optimum stimulation. *Arthritis Rheum* **34**:393, 1991
49. Stanek G, O'Connell S, Cimmino M et al: European Union concerted action on risk assessment in Lyme Borreliosis: Clinical case definitions for Lyme borreliosis. *Wien Klin Wochenschr* **108**:741, 1996
50. Wormser GP et al: Association of specific subtypes of *Borrelia burgdorferi* with hematogenous dissemination in early Lyme disease. *J Infect Dis* **180**:720, 1999
51. Steere AC, Schoen RT, Taylor E: The clinical evolution of Lyme arthritis. *Ann Intern Med* **107**:725, 1987
52. Berger BW: Cutaneous manifestations of Lyme borreliosis. *Rheum Dis Clin North Am* **15**:627, 1989
53. Berger BW et al: Cultivation of *Borrelia burgdorferi* from human tick bite sites: A guide to the risk of infection. *J Am Acad Dermatol* **32**:184, 1995
54. Melski JW: Language, logic, and Lyme disease. *Arch Dermatol* **135**:1398, 1999

55. Berger BW, Clemmensen OJ, Ackerman AB: Lyme disease is a spirochetosis. A review of the disease and evidence for its cause. *Am J Dermatopathol* 5:111, 1983
56. Malane MS, Grant-Kels JM, Feder HM Jr, Luger SW: Diagnosis of Lyme disease based on dermatologic manifestations. *Ann Intern Med* 114:490, 1991
57. Goldberg NS et al: Vesicular erythema migrans. *Arch Dermatol* 128:1495, 1992
58. Wu YS et al: Atypical cutaneous lesions of Lyme disease. *Clin Exp Dermatol* 18:434, 1993
59. Duray PH, Asbrink E, Weber K: The cutaneous manifestations of human Lyme disease: A widening spectrum. *Adv Dermatol* 4:255; discussion 276, 1989
60. Mullegger RR et al: Differential expression of cytokine mRNA in skin specimens from patients with erythema migrans or acrodermatitis chronica atrophicans. *J Invest Dermatol* 115:1115, 2000
61. Asbrink E, Hovmark A: Early and late cutaneous manifestations in Ixodes-borne borreliosis (erythema migrans borreliosis, Lyme borreliosis). *Ann N Y Acad Sci* 539:4, 1988
62. Duray PH: Clinical pathologic correlations of Lyme Disease. *Rev Infect Dis* 11:S1487, 1989
63. Cordoliani F et al: Atypical Lyme borreliosis in an HIV-infected man. *Br J Dermatol* 137:437, 1997
64. Berger BW et al: Cultivation of *Borrelia burgdorferi* from erythema migrans lesions and perilesional skin. *J Clin Microbiol* 30:359, 1992
65. Eisendle K, Grabner T, Zelger B: Focus floating microscopy: "Gold standard" for cutaneous borreliosis? *Am J Clin Pathol* 127:213, 2007
66. Kaufman LD et al: Late cutaneous Lyme disease: Acrodermatitis chronica atrophicans. *Am J Med* 86:828, 1989
67. Gellis SE, Stadecker MJ, Steere AC: Spirochetes in atrophic skin lesions accompanied by minimal host response in a child with Lyme disease. *J Am Acad Dermatol* 25:395, 1991
68. DiCaudo DJ et al: Acrodermatitis chronica atrophicans in the United States: Clinical and histopathologic features of six cases. *Cutis* 54:81, 1994
69. Burgdorf WH et al: Acrodermatitis chronica atrophicans. *Int J Dermatol* 18:595, 1979
70. Picken RN et al: Molecular subtyping of *Borrelia burgdorferi* sensu lato isolates from five patients with solitary lymphocytoma. *J Invest Dermatol* 108:92, 1997
71. Duray PH: The surgical pathology of human Lyme disease. An enlarging picture. *Am J Surg Pathol* 11(Suppl. 1):47, 1987
72. Asbrink E, Brehmer-Andersson E, Hovmark A: Acrodermatitis chronica atrophicans—a spirochetosis. Clinical and histopathological picture based on 32 patients; course and relationship to erythema chronicum migrans Afzelius. *Am J Dermatopathol* 8:209, 1986
73. Buechner SA, Ruffli T, Erb P: Acrodermatitis chronica atrophicans: A chronic T-cell-mediated immune reaction against *Borrelia burgdorferi*? Clinical, histologic, and immunohistochemical study of five cases. *J Am Acad Dermatol* 28:399, 1993
74. Ilowite NT: Muscle, reticuloendothelial, and late skin manifestations of Lyme disease. *Am J Med* 98:63S, 1995
75. Silberer M et al: Downregulation of class II molecules on epidermal Langerhans cells in Lyme borreliosis. *Br J Dermatol* 143:786, 2000
76. Kaya G et al: Chronic borreliosis presenting with morphea- and lichen sclerosus et atrophicus-like cutaneous lesions. a case report. *Dermatology* 202:373, 2001
77. Tuffanelli D: Do some patients with morphea and lichen sclerosus et atrophicans have a *Borrelia* infection? *Am J Dermatopathol* 9:371, 1987
78. Espana A et al: Periarticular fibrous nodules in Lyme borreliosis. *Br J Dermatol* 125:68, 1991
79. Marsch WC, Mayet A, Wolter M: Cutaneous fibroses induced by *Borrelia burgdorferi*. *Br J Dermatol* 128:674, 1993
80. Granter SR, Barnhill RL, Duray PH: Borrelial fasciitis: Diffuse fasciitis and peripheral eosinophilia associated with *Borrelia* infection. *Am J Dermatopathol* 18:465, 1996
81. Stanek G et al: Shulman syndrome, a scleroderma subtype caused by *Borrelia burgdorferi*? *Lancet* 1:1490, 1987
82. Abele DC, Anders KH: The many faces and phases of borreliosis. I. Lyme disease. *J Am Acad Dermatol* 23:167, 1990
83. Marsch WC, Wolter M, Mayet A: Juxta-articular fibrotic nodules in *Borrelia* infection—ultrastructural details of therapy-induced regression. *Clin Exp Dermatol* 19:394, 1994
84. Hofer T, Goldenberger D, Itin PH: Anetoderma and borreliosis: Is there a pathogenetic relationship? *Eur J Dermatol* 13:399, 2003
85. Hauser W: Dermatitis atrophicans maculosa. *Dermatol Venerol* 2:867, 1958

86. Hovmark A, Asbrink E, Olsson I: The spirochetal etiology of lymphadenosis benigna cutis solitaria. *Acta Derm Venereol* **66**:479, 1986
87. Abele DC, Anders KH, Chandler FW: Benign lymphocytic infiltration (Jessner-Kanof): Another manifestation of borreliosis? *J Am Acad Dermatol* **21**:795, 1989
88. Garbe C et al: *Borrelia burgdorferi*-associated cutaneous B cell lymphoma: Clinical and immunohistologic characterization of four cases. *J Am Acad Dermatol* **24**:584, 1991
89. Goodlad JR et al: *Borrelia burgdorferi*-associated cutaneous marginal zone lymphoma: A clinicopathological study of two cases illustrating the temporal progression of *B. burgdorferi*-associated B-cell proliferation in the skin. *Histopathology* **37**:501, 2000
90. Slater DN: *Borrelia burgdorferi*-associated primary cutaneous B-cell lymphoma. *Histopathology* **38**:73, 2001
91. Roggero E et al: Eradication of *Borrelia burgdorferi* infection in primary marginal zone B-cell lymphoma of the skin. *Hum Pathol* **31**:263, 2000
92. Kutting B et al: *Borrelia burgdorferi*-associated primary cutaneous B cell lymphoma: Complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. *J Am Acad Dermatol* **36**:311, 1997
93. Steere AC: Lyme disease. *N Engl J Med* **321**:586, 1989
94. Pachner AR, Steere AC: The triad of neurologic manifestations of Lyme disease: Meningitis, cranial neuritis, and radiculoneuritis. *Neurology* **35**:47, 1985
95. Garin C, Bujadoux A: Paralysie par les Tiques. *J Méd Lyon* **71**:765, 1922
96. Bannwarth A: Chronische lymphocytare Meningitis, entzündliche Polyneuritis und "Rheumatismus." Ein Beitrag zum Problem "Allergie und Nervensystem." *Archiv für Psychiatrie und Nervenkrankheiten* **113**:284, 1941
97. Oschmann P et al: Stages and syndromes of neuroborreliosis. *J Neurol* **245**:262, 1998
98. Logigian EL, Steere AC: Clinical and electrophysiologic findings in chronic neuropathy of Lyme disease. *Neurology* **42**:303, 1992
99. Cox J, Krajden M: Cardiovascular manifestations of Lyme disease. *Am Heart J* **122**:1449, 1991
100. van der Linde MR, Crijns HJ, Lie KI: Transient complete AV block in Lyme disease. Electrophysiologic observations. *Chest* **96**:219, 1989
101. Steere AC et al: Lyme carditis: Cardiac abnormalities of Lyme disease. *Ann Intern Med* **93**:8, 1980
102. Stanek G et al: Isolation of *Borrelia burgdorferi* from the myocardium of a patient with long-standing cardiomyopathy. *N Engl J Med* **322**:249, 1990
103. Sonnesyn SW et al: A prospective study of the seroprevalence of *Borrelia burgdorferi* infection in patients with severe heart failure. *Am J Cardiol* **76**:97, 1995
104. Mikkila HO et al: The expanding clinical spectrum of ocular Lyme borreliosis. *Ophthalmology* **107**:581, 2000
105. Karma A et al: Diagnosis and clinical characteristics of ocular Lyme borreliosis. *Am J Ophthalmol* **119**:127, 1995
106. Elliott DJ, Eppes SC, Klein JD: Teratogen update: Lyme disease. *Teratology* **64**:276, 2001
107. Rothermel H, Hedges TR III, Steere AC: Optic neuropathy in children with Lyme disease. *Pediatrics* **108**:477, 2001
108. Krause PJ et al: Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness. *JAMA* **275**:1657, 1996
109. Levin ML, Fish D: Acquisition of coinfection and simultaneous transmission of *Borrelia burgdorferi* and *Ehrlichia phagocytophila* by *Ixodes scapularis* ticks. *Infect Immun* **68**:2183, 2000
110. De Martino SJ, Carlyon JA, Fikrig E: Coinfection with *Borrelia burgdorferi* and the agent of human granulocytic ehrlichiosis. *N Engl J Med* **345**:150, 2001
111. Steere AC et al: Autoimmune mechanisms in antibiotic treatment-resistant Lyme arthritis. *J Autoimmun* **16**:263, 2001
112. Steere AC et al: Treatment of Lyme arthritis. *Arthr Rheum* **37**:878, 1994
113. Gross DM et al: Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. *Science* **281**:703, 1998
114. Weinstein A, Britchokov M: Lyme arthritis and post-Lyme disease syndrome. *Curr Opin Rheumatol* **14**(4):383-387, 2002
115. Fallon BA et al: Regional cerebral blood flow and cognitive deficits in chronic Lyme disease. *J Neuropsychiatry Clin Neurosci* **15**:326, 2003
116. Kalish RA et al: Evaluation of study patients with Lyme disease, 10–20-year follow-up. *J Infect Dis* **183**:453, 2001
117. Seltzer EG et al: Long-term outcomes of persons with Lyme disease. *JAMA* **283**:609, 2000

118. De Koning J, Bosma RB, Hoogkamp-Korstanje JA: Demonstration of spirochaetes in patients with Lyme disease with a modified silver stain. *J Med Microbiol* 23:261, 1987
119. Wormser GP et al: Comparison of the yields of blood cultures using serum or plasma from patients with early Lyme disease. *J Clin Microbiol* 38:1648, 2000
120. Coyle P: Lyme disease. In: *Continuum: Lifelong Learning in Neurology*. edited by Aaron E Miller. Philadelphia, Lippincott Williams & Wilkins, August 1999
121. Wormser GP et al: Improving the yield of blood cultures for patients with early Lyme disease. *J Clin Microbiol* 36:296, 1998
122. Nocton JJ et al: Detection of *Borrelia burgdorferi* DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. *N Engl J Med* 330:229, 1994
123. CDC: Notice to readers: Caution regarding testing for Lyme disease. *MMWR Morb Mortal Wkly Rep* 54:125, 2005
124. Magnarelli LA, Anderson JF: Enzyme-linked immunosorbent assays for the detection of class-specific immunoglobulins to *Borrelia burgdorferi*. *Am J Epidemiol* 127:818, 1988
125. Magnarelli LA et al: Cross-reactivity of nonspecific treponemal antibody in serologic tests for Lyme disease. *J Clin Microbiol* 28:1276, 1990
126. Nocton JJ, Steere AC: Lyme disease. *Adv Intern Med* 40:69, 1995
127. Tierno PMJ, Cadet-Legros J: Methods comparison for diagnosis of Lyme disease. *Lab Med* 27:542, 1996
128. Jansson C et al: Analysis of *Borrelia burgdorferi* IgG antibodies with a combination of IgG ELISA and VlsE C6 peptide ELISA. *Clin Microbiol Infect* 11:147, 2005
129. Goettner G et al: Improvement of Lyme borreliosis serodiagnosis by a newly developed recombinant immunoglobulin G (IgG) and IgM line immunoblot assay and addition of VlsE and DbpA homologues. *J Clin Microbiol* 43:3602, 2005
130. Ledue TB, Collins MF, Craig WY: New laboratory guidelines for serologic diagnosis of Lyme disease: Evaluation of the two-test protocol. *J Clin Microbiol* 34:2343, 1996
131. Kalish RA et al: Persistence of immunoglobulin M or immunoglobulin G antibody responses to *Borrelia burgdorferi* 10–20 years after active Lyme disease. *Clin Infect Dis* 33:780, 2001
132. Feder HM Jr et al: Persistence of serum antibodies to *Borrelia burgdorferi* in patients treated for Lyme disease. *Clin Infect Dis* 15:788, 1992
133. Wormser GP et al: Effect of *Borrelia burgdorferi* genotype on the sensitivity of C6 and 2-tier testing in North American patients with culture-confirmed Lyme disease. *Clin Infect Dis* 47:910, 2008
134. Branda JA et al: 2-tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. *Clin Infect Dis* 50:20, 2010
135. Wormser GP et al: The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 43:1089, 2006
136. Nadelman RB et al: Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. *Ann Intern Med* 117:273, 1992
137. Dattwyler RJ et al: Amoxicillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. *Lancet* 336:1404, 1990
138. Wormser GP et al: Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 138:697, 2003
139. Klempner MS et al: Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. *N Engl J Med* 345:85, 2001
140. Nadelman RB et al: Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an *Ixodes scapularis* tick bite. *N Engl J Med* 345:79, 2001
141. Steere AC et al: Vaccination against Lyme disease with recombinant *Borrelia burgdorferi* outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. *N Engl J Med* 339:209, 1998
142. Wormser GP et al: Advances in the treatment and prevention of Lyme borreliosis. *Wien Klin Wochenschr* 117:381, 2005
143. Administration, FDA: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3680b2_06.doc
144. Abbott A: Lyme disease: Uphill struggle. *Nature* 439:524, 2006
145. Hayes EB, Piesman J: How can we prevent Lyme disease? *N Engl J Med* 348:2424, 2003

